Payload Information
General Information of This Payload
Payload ID | PAY0ALSVY |
|||||
---|---|---|---|---|---|---|
Name | Methylated-beta-Cyclodextrin/Pluronic P103-based polyrotaxane (Me-PRX) |
|||||
Synonyms |
Methylated-beta-Cyclodextrin/Pluronic P103-based polyrotaxane (Me-PRX)
Click to Show/Hide
|
|||||
Target(s) | . |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Trastuzumab-Me-PRX conjugate [Investigative]
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.50 uM
|
Negative HER2 expression (HER2-) | ||
Method Description |
Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
|
||||
In Vitro Model | Endocervical adenocarcinoma | HeLa cells | CVCL_0030 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
6.75 uM
|
Positive HER2 expression (HER2+++/++) | ||
Method Description |
Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
|
||||
In Vitro Model | Lung adenocarcinoma | Calu-3 cells | CVCL_0609 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
7.02 uM
|
Positive HER2 expression (HER2+++/++) | ||
Method Description |
Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
|
||||
In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.